文献速递炎症性肠病

炎症性肠病生物制剂降剂量治疗的有效性:一项系统综述

Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

本系统综述检索EMBASE、MEDLINE和Cochrane对照试验中心注册库至2019年10月,纳入20项研究共995例缓解期炎症性肠病成人患者,评估生物制剂降剂量的有效性。结果显示降剂量后临床复发率为0%-54%,1年临床复发率为7%-50%;证据质量极低,降剂量似乎与高复发率相关,需更多对照前瞻性研究。

要点

  • 降剂量后临床复发率为0%-54%(17项研究),1年复发率为7%-50%(6项研究)。
  • 18项研究存在高偏倚风险,主要因缺乏对照组,证据质量极低。
  • 降剂量似乎与高临床复发率相关,需更多对照前瞻性研究明确有效性及成功预测因素。

核心结论

  • 降剂量似乎与高临床复发率相关,但证据质量极低。
  • 需要更多对照前瞻性研究来明确生物制剂降剂量的有效性并识别成功的预测因素。

研究设计与样本

  • 系统综述,检索EMBASE、MEDLINE和Cochrane对照试验中心注册库自建库至2019年10月。
  • 纳入标准为涉及缓解期炎症性肠病成人患者生物制剂降剂量的随机对照试验和观察性研究。
  • 排除仅涉及生物制剂停药的研究及缺乏降剂量后结局的研究。
  • 共纳入20项符合标准的研究,包括18项观察性研究(4项前瞻性、14项回顾性)、1项非随机对照试验和1项随机对照试验的亚组分析,共995例患者。
  • 7项研究纳入克罗恩病患者,1项纳入溃疡性结肠炎患者,12项同时纳入两者;采用纽卡斯尔-渥太华量表评估偏倚风险。

主要发现

  • 降剂量生物制剂治疗的患者中,临床复发率为0%-54%(17项研究)。
  • 1年临床复发率为7%-50%(6项研究)。
  • 18项研究被认为存在高偏倚风险,主要因缺乏对照组。

局限性

  • 证据质量极低。
  • 18项研究存在高偏倚风险,主要因缺乏对照组。
  • 需要更多对照前瞻性研究来明确生物制剂降剂量的有效性并识别成功的预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: De-escalation of biologic therapy is a commonly encountered clinical scenario. Although biologic discontinuation has been associated with high rates of relapse, the effectiveness of dose de-escalation is unclear. This review was performed to determine the effectiveness of dose de-escalation of biologic therapy in inflammatory bowel disease. METHODS: We searched EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials from inception to October 2019. Randomized controlled trials and observational studies involving dose de-escalation of biologic therapy in adults with inflammatory bowel disease in remission were included. Studies involving biologic discontinuation only and those lacking outcomes after dose de-escalation were excluded. Risk of bias was assessed using the Newcastle-Ottawa Scale. RESULTS: We identified 1,537 unique citations with 20 eligible studies after full-text review. A total of 995 patients were included from 18 observational studies (4 prospective and 14 retrospective), 1 nonrandomized controlled trial, and 1 subgroup analysis of a randomized controlled trial. Seven studies included patients with Crohn's disease, 1 included patients with ulcerative colitis, and 12 included both. Overall, clinical relapse occurred in 0%-54% of patients who dose de-escalated biologic therapy (17 studies). The 1-year rate of clinical relapse ranged from 7% to 50% (6 studies). Eighteen studies were considered at high risk of bias, mostly because of the lack of a control group. DISCUSSION: Dose de-escalation seems to be associated with high rates of clinical relapse; however, the quality of the evidence was very low. Additional controlled prospective studies are needed to clarify the effectiveness of biologic de-escalation and identify predictors of success.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Little DHW, Tabatabavakili S, Shaffer SR, et al. Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2020. PMID: 33156094. doi:10.14309/ajg.0000000000000783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。